Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant that is designed to address unmet needs in anticoagulation therapy.
Cadrenal completed the technical transfer and manufacturing of its tecarfarin drug substance in accordance with current good manufacturing practices (cGMP) earlier this year at a U.S. site of a leading global Contract Development and Manufacturing Organization (CDMO). Manufacturing of the tecarfarin drug product candidate is currently underway.
'We are pleased with the important progress we have made with the supply chain and cGMP manufacturing process for tecafarin,' said Quang X. Pham, Chairman & CEO. 'This is a key milestone as we support our clinical development strategy and tecarfarin's potential to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation.'
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal's lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for several indications, extensive clinical and real-world data have shown it can have significant, serious side effects.
Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).
Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit https://www.cadrenal.com/ and connect with us on LinkedIn.
Safe Harbor
Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potentially,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding tecarfarin's potential to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation and pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to provide clinical benefits for patients with cardiovascular disease who require chronic VKA anticoagulation, the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250515408603/en/
CONTACT: Corporate and Investor Relations
Paul Sagan
LaVoieHealthScience
(617) 865-0041
[email protected]
Andrew Korda
LaVoieHealthScience
(617) 865-0043
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA FLORIDA
INDUSTRY KEYWORD: HEALTH OTHER HEALTH GENERAL HEALTH CLINICAL TRIALS PHARMACEUTICAL CARDIOLOGY BIOTECHNOLOGY
SOURCE: Cadrenal Therapeutics, Inc.
Copyright Business Wire 2025.
PUB: 05/15/2025 07:30 AM/DISC: 05/15/2025 07:29 AM
http://www.businesswire.com/news/home/20250515408603/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Amazon (AMZN) Gets Price Target Hike After Strong Quarterly Performance
Inc. (NASDAQ:) is one of the . On August 11, Freedom Broker analyst Egor Tolmachev raised the price target on the stock to $255.00 (from $240.00) while maintaining a Hold rating. The investment bank noted how Amazon has delivered strong financial results for the second quarter, surpassing both market expectations and its own guidance across all segments. Retail efficiency gains were particularly noted. The firm did note that AWS performance was mixed and Q3 profit forecast was cautious. Nevertheless, it revised its financial forecast based on its confidence in the company's ability to mitigate geopolitical risk and monetize continued logistics improvements. 'Q3 guidance came in well above revenue expectations but below profit forecasts, marking a second area of perceived weakness in the release. We view this as prudent management positioning in light of heightened geopolitical uncertainty. We have revised our financial forecasts upward, reflecting confidence in Amazon's ability to mitigate geopolitical risk and monetize continued logistics improvements. Despite the negative share price reaction, we see upside potential and reiterate our Buy rating, raising our target price from $240 to $255.' Inc. (NASDAQ:AMZN) is an American technology company offering e-commerce, cloud computing, and other services, including digital streaming and artificial intelligence solutions. While we acknowledge the potential of AMZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Business Wire
an hour ago
- Business Wire
Consumer Rights Law Firm Hagens Berman Launches Investigation into Real Estate Agent Practices
SEATTLE--(BUSINESS WIRE)--Attorneys at national consumer-rights law firm Hagens Berman have initiated an investigation into real estate agent practices regarding home sale transactions. If we find that consumers were misled, we're prepared to act to hold companies responsible. Share The investigation comes on the heels of a blockbuster settlement totaling $1 billion in Burnett v. National Association of Realtors, which alleges that real estate brokerage companies and the National Association of Realtors caused home sellers to pay illegally inflated broker commissions through unlawful practices. Hagens Berman serves as co-lead counsel in the antitrust litigation. If you sold a home since 2021, you may be impacted by recently uncovered practices and could be eligible to potential compensation. Attorneys encourage those who have sold a home with the assistance of an online real estate agent since 2021 to contact the law firm to learn more about their rights. Real Estate's Real Cost Hagens Berman's research has identified allegedly deceptive practices in the home selling process that may affect consumers nationwide. Brokers, which offer home selling and buying services to millions across the U.S. each year, may be violating consumer rights and causing home sellers to overpay. 'Our investigation is about making sure the real estate market is fair and just for consumers,' says Steve W. Berman, managing partner of Hagens Berman and co-lead counsel in the recentlandmark real estate antitrust case. 'Buying or selling a home is one of the biggest financial decisions people make. Our job is to make sure families can trust the process and aren't taken advantage of. If we find that consumers were misled, we're prepared to act to hold companies responsible.' . About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation law firm with a tenacious drive for achieving real results for those harmed by corporate negligence and fraud. Since its founding in 1993, the firm's determination has earned it numerous national accolades, awards and titles of 'Most Feared Plaintiff's Firm,' MVPs and Trailblazers of class-action law. More about the law firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw.
Business Wire
an hour ago
- Business Wire
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc. ('Vyome'), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (Nasdaq: RSLS). The post-merger company will trade at the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol 'HIND.' About Vyome Vyome is building a healthcare platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit Visit us on social media: Facebook X LinkedIn Forward-Looking Statements Certain statements made in this press release are 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'target,' 'believe,' 'expect,' 'will,' 'shall,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' 'forecast,' 'intend,' 'plan,' 'project,' 'outlook', and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this report regarding the merger, including the benefits of the merger, revenue opportunities, anticipated future financial and operating performance, and results, including estimates for growth. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vyome's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (a) the occurrence of any event, change, or other circumstances relating to the combined company; (b) failure to obtain the necessary consents and approvals; (c) the risk that the merger disrupts current plans and operations as a result of the announcement and consummation of the merger; (e) costs related to the merger; and (f) changes in applicable laws or regulations. Vyome cautions that the foregoing list of factors is not exhaustive. Vyome cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vyome does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, whether as a result of new information, future events, or otherwise, except as may be required by applicable law.
